Raising funding for startups in Silicon Valley is a low probability game. Fewer than 1% who try actually succeed.
Outside the Valley, the startup ecosystems are mostly immature, and the probability gets even lower.
The bar to raise seed funding is getting higher and higher. Seed investors are mostly operating as growth investors, expecting that the entrepreneur will somehow manage to bridge the gap and bring a concept to realization. In fact, what these investors really want is to invest in businesses that have traction, not just validation.
In short, they want to come to the rescue of victory.
The toughest round of funding an entrepreneur will seek to raise is pre-seed investment. It has the lowest probability of success, the highest amount of ambiguity, is poorly defined, and causes the greatest amount of confusion and missteps out there.
Over 99% of the entrepreneurs who seek financing are rejected.
So, my humble advice to all entrepreneurs: please learn to assess your own probability of getting funded.
For our Seed Capital series of podcasts and blog interviews, I’ve interviewed hundreds of investors, especially micro-VCs and angels who play an important role in the early-stage game.
As I expected, a large number of investors are still chasing Unicorns. They are interested in investing in companies that will go from 0 to $100M in 5-7 years. And they will consume a great deal of capital in the quest of hitting the coveted billion-dollar valuation mark.
However, I am pleased to report that I have spoken with a good number of investors who recognize the niche opportunities.
Sramana Mitra: There is the opportunity for gene editing before a baby is born. Then there is the opportunity for gene editing later in life.
Sergey Jakimov: There is a huge ethical component. If you leave that aside, what makes total sense is identifying potential life-threatening diseases or disabilities with DNA-driven factors for unborn babies and introducing these changes early on so that the new person gets to live a normal life. That’s totally fine by me.
>>>Sramana Mitra: Are you looking for something in this DNA testing and sequencing area that you haven’t found yet?
Sergey Jakimov: I would be looking for a merge between DNA sequencing capacity and actionable insights based on that. I would be looking at the comprehensive model where the company offers you DNA sequencing and a comprehensive report with some supplement-based insights or potential diagnostic-based insight or non-prescription interventions to mitigate risks.
>>>Sramana Mitra: Let’s switch gears to another category. Pick another category where there is a heavy computer science element.
Sergey Jakimov: Another interesting one is digital health. If we’re talking longevity, it’s of course aging clocks and all sorts of consumer-facing risk calculators. That’s another very interesting angle of how we taught algorithms to work with clinical data or user-reported data as well as how we made it consumer-facing and consumer-digestible.
>>>Sramana Mitra: I want to double-click down on a bunch of areas that are broadly relevant to digital health. What you said about applying AI to drug discovery is of interest. Any kind of quantified health measures is also of interest.
The intersection of computer science and biology is where our audience would find the most useful insight. What is the state of the union and where are you playing? What are some of the case studies in your portfolio?
>>>Sergey Jakimov is Co-founder and Partner at LongeVC, a firm focused on the Longevity space. We discuss trends and opportunities in this sector full of whitespaces waiting for the entrepreneur’s magic touch.
Sramana Mitra: Give us a little bit of an introduction about your background as well as about LongeVC.
>>>If you have been bootstrapping and think you are ready for investors, you need to learn how investors think. First, please study our free Bootstrapping course and the Investor Introductions page. Then, start looking for entrepreneur – investor fit. Today, I introduce you to Cindy Padnos, Illuminate Ventures.
Cindy Padnos, Founder and Managing Partner at Illuminate Ventures, discusses a topic that we’ve been highlighting recently: the need for multiple seed rounds as a way to bridge the Series A gap. You can listen to a podcast of our conversation here or watch the roundtable video below:
Sramana Mitra: Tell us about Illuminate Ventures. What is the focus of the firm? How big is the fund? What sized investments do you make?
Cindy Padnos: We’re on our third fund. It’s a $30 million fund. Our focus is exclusively in the enterprise or B2B category. We invest in startups that are SaaS business applications, cloud computing, mobile software targeted towards the enterprise.